• TransCode Therapeutics posted net loss of $34.7 million for fiscal 2025, widening from $16.8 million a year earlier.
• Operating loss widened to $28 million from $15.7 million, while revenue remained at no revenue.
• Research and development expense climbed to $13.4 million from $9.7 million, while general and administrative expense rose to $14.6 million from $6 million due to $8.8 million of acquisition-related transaction costs.
• Business updates included completion of most of the Phase I/II TTX-MC138 trial by end-2025 with no significant safety or dose-limiting toxicities reported, while a Phase 2a trial is expected to start in first half of 2026.
• TransCode ended 2025 with cash of $17.8 million and expects it to fund operations through about year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-043810), on April 15, 2026, and is solely responsible for the information contained therein.